Effect of Catheter Duration on Prostate Laser Enucleation Surgery Outcomes in Patients With Urinary Retention

NCT07603011 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2026-05-22

No results posted yet for this study

Summary

Benign Prostatic Obstruction (BPO) is a common condition in aging men that can lead to urinary retention, often requiring the use of an indwelling urinary catheter. While laser enucleation of the prostate (such as HoLEP, ThuLEP or ThuFLEP) is a safe and effective surgical treatment, it is not well understood how the length of time a patient spent with a urethral catheter before surgery affects the final surgical outcomes. By analyzing patient data from multiple centers of the Minimally Invasive Urology Society, this study aims to evaluate the impact of preoperative catheterization duration on functional outcomes.

Conditions

  • Urinary Retention
  • Benign Prostate Obstruction (BPO)

Interventions

PROCEDURE

Laser Enucleation of the Prostate (HoLEP, ThuLEP, ThuFLEP)

Patients undergo endoscopic laser enucleation of the prostate using either Holmium or Thulium laser platforms, depending on the standard equipment and clinical preference of the participating center. The procedure involves the anatomical enucleation of the prostatic adenoma from the surgical capsule, followed by intravesical morcellation of the enucleated tissue. All surgeries are performed by urologists according to established surgical protocols.

Sponsors & Collaborators

  • Ankara University

    collaborator OTHER
  • Dokuz Eylul University

    collaborator OTHER
  • Erol Olcok Corum Training and Research Hospital

    collaborator OTHER
  • Gazi University

    collaborator OTHER
  • Marmara University

    collaborator OTHER
  • Samsun Education and Research Hospital

    collaborator OTHER
  • Ondokuz Mayıs University

    collaborator OTHER
  • Cukurova University

    collaborator OTHER
  • Izmir Metropolitan Municipality Esrefpasa Hospital

    collaborator UNKNOWN
  • Tepecik Training and Research Hospital

    collaborator OTHER
  • Eskişehir Osmangazi University Medicine Faculty Hospital

    lead OTHER

Principal Investigators

  • Suleyman Oner, MD · Eskisehir Osmangazi University Faculty of Medicine Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-04
Primary Completion
2028-02-04
Completion
2029-02-04

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07603011 on ClinicalTrials.gov